Jinxin Fertility Group Limited (1951.HK)
HKSE · HKD · Healthcare · Medical Care Facilities
HK$2.25 (-1.32%) as of
Key statistics
- Market cap
- 5.95B
- P/E (TTM)
- 28.06
- Forward P/E
- 14.93
- EPS (TTM)
- 0.080
- Dividend yield
- 1.84%
- 52-week range
- 1.920 – 2.670
- Beta
- 0.77
- Revenue (TTM)
- 2.73B
- Profit margin
- 6.26%
- Analyst target
- HK$3.19
- Volume
- 3.54M
About Jinxin Fertility Group Limited
Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and internationally. The company provides two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; obstetrics, gynecology, urology, internal medicine, and pediatrics medical services; ambulatory surgery center facilities services; and ancillary medical services. Further, it provides pre-implantation genetic screening testing, management consultancy, postpartum and rehabilitation care, maternal-child nursing, and other hospital- derived services. Additionally, the company is involved in property investment, and real estate development and operation activities; sale of medicines, consumables, and equipment; research and development of IVF related projects, including scientific research and related commercialization; and operates restaurant. Jinxin Fertility Group Limited was founded in 1951 and is headquartered in Chengdu, China.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Headquarters
- Chengdu, China
- Employees
- 3,128
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.